Afatinib + bevacizumab combination therapy in EGFR‐mutant NSCLC patients with osimertinib resistance: Protocol of an open‐label, phase II, multicenter, single‐arm trial

INTRODUCTION: As most patients with epidermal growth factor receptor (EGFR)‐mutant non‐small cell lung cancer (NSCLC) develop progressive disease after treatment with osimertinib, it is important to develop more effective treatment options. Afatinib has been shown to be more effective in in vitro st...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Thorac Cancer
Hlavní autoři: Kobayashi, Nobuaki, Hashimoto, Hisashi, Kamimaki, Chisato, Nagasawa, Ryo, Tanaka, Katsushi, Kubo, Sousuke, Katakura, Seigo, Chen, Hao, Hirama, Nobuyuki, Ushio, Ryota, Aoki, Ayako, Nakashima, Kentaro, Teranishi, Shuhei, Manabe, Saki, Watanabe, Hiroki, Horita, Nobuyuki, Watanabe, Keisuke, Hara, Yu, Yamamoto, Masaki, Kudo, Makoto, Piao, Hongmei, Kaneko, Takeshi
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley & Sons Australia, Ltd 2020
Témata:
Original Articles
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7396380/
https://ncbi.nlm.nih.gov/pubmed/32495514
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13503
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky